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Arterial stiffness is increasingly recognized as an important determinant of cardiovascular risk and may be directly
involved in the process of atherosclerosis. As atherosclerosis leads to increased arterial resistance and decrease the flow
propagation speed within the arterial lumen, a similar decrease in aortic flow propagation with increased downstream
resistance is detected, so aortic flow propagation velocity AVP was evaluated in many studies as a new parameter of
aortic stiffness.
Aim: To measure arterial stiffness using the new parameter AVP and compare it to flow mediated dilatation FMD
as a parameter of endothelial dysfunction in patients with metabolic syndrome MS.
Methods: AVP (assessed by transthoracic echocardiography) and FMD (assessed by brachial artery reactiv-
ity test) were measured in 100 patients with MS (Group 1) and were compared to 14 normal subjects
(Group 2).
Results: Patients with MS had significantly lower values of AVP as compared to the normal subjects;
36 þ 5 cm/s vs 57 þ 5, p < 0.05, and lower FMD; 6% þ 1 vs 17 þ 3 p < 0.05 as well, there was significant corre-
lations between AVP and FMD (r = 0.89, p < 0.001).
Conclusion: Transthoracic echocardiographic determination of AVP is a simple practical method and corre-
lates well with FMD in patients with MS.
 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Arterial stiffness is a growing epidemic associ-ated with increased risk of cardiovascular
events, dementia, and death. Decreased compli-ance of the central vasculature alters arterial pres-
sure and flow dynamics and impacts cardiac
performance and coronary perfusion [1].
Increased central arterial stiffening is not only a
hallmark of the aging process [2], but thee CCBY-
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betes and chronic renal compromise [3,4].
In patients with diabetes and metabolic syn-
drome (MS), arterial stiffening is consistently
observed across all age groups. For example,
increased arterial stiffness and abnormal endothe-
lial reactivity is already present in obese children
with metabolic syndrome [5]. A core feature
appears to be insulin resistance, because central
arterial stiffness and insulin resistance are posi-
tively correlated. Furthermore, the extent of meta-
bolic changes predicts arterial stiffness in a dose-
dependent fashion [6]. Chronic hyperglycemia
and hyperinsulinemia increases the local activity
of the renin-angiotensin-aldosterone system and
expression of angiotensin type I receptor in vascu-
lar tissue [7], promoting development of wall
hypertrophy and fibrosis [8].
A large population-based study of vascular
health suggested that hyperglycemia was related
to both endothelial dysfunction and arterial stiff-
ness [9]. Greater glycemic variability measured
by continuous subcutaneous glucose monitoring
is also associated with endothelial dysfunction in
adults with normoglycemia, hyperglycemia, and
type 2 diabetes [10].
Aortic stiffness has been assessed using param-
eters, such as pulse-wave velocity, aortic strain,
compliance, and distinsibility. These parameters
can be measured using applanation tonometry,
oscillometry, echocardiography, and velocity-
encoded magnetic resonance imaging [11–16].
Recently, aortic-flow propagation velocity (AVP)
in the descending aorta using color M-Mode was
used in the assessment of arterial stiffness [17–
19]. Our aim in this study was to measure arterial
stiffness using the new parameter (AVP) and com-
pare it to the brachial-artery reactivity test as a
parameter of endothelial dysfunction in patients
with metabolic syndrome.2. Materials and methods
One hundred patients meeting the criteria of
metabolic syndrome (MS) according to the
National Cholesterol Education Program Adult
Treatment Panel III [20] were included in the
study (Group 1) and were compared to 14 normal
individuals (Group 2). All patients were recruited
from Tanta University Hospital, Tanta, Egypt from
July 2013 to March 2014.
Exclusion criteria: (1) patients who did not meet
the criteria of (MS) with isolated primiary hyper-
tension, diabetes mellietus, or dyslipidemia; (2)
patients with aortic valve disease, renal disease,and coronary artrey disease; (3) patients with reti-
nopathies and nephropathy; and (4) women tak-
ing contraceptive pills. All patients gave
informed consent, and the study was approved
by the Institutional Ethics Committee (Tanta
University Hospital).
Patients and normal individuals were subjected
to full clinical examination, electrocardiogram,
abdominal ultrasonography to detect fatty liver,
echocardiographic examination, full laboratory
investigations, including lipid and liver profiles,
fasting blood sugar (FBS), uric acid (UA), and c-
reactive protein levels (CRP), and a brachial artrey
reactivity test (BART). Viral hepatitis serology
markers were examined in patients with high liver
enzymes.
The echocardiographic examination was per-
formed at rest by an experienced operator who
was blinded to the clinical conditions of the partic-
ipants. Patients were examined in the left lateral
decubitus position using a commercially available
echocardiographic device (Vivid 7, GE Healthcare,
Madison, WI, USA) with a 3.0 MHz transducer to
measure left ventricular dimensions and function,
diastolic function (graded as normal 0 or 1, 2, 3,
and 4), E/e0 as an indication of filling pressure,
and septal diameter (IVS).
From the supine position, color M-mode Dop-
pler recordings were obtained with the cursor par-
allel to the main flow direction in the descending
aorta. The Color Doppler Nyquist limit was
adapted to 30–50 cm/s and was switched to M-
mode with a recorder sweep rate of 200 mm/s.
An M-mode spatiotemporal velocity map with
the shape of a flame was displayed. If the slope
of the flame was unclear, baseline shifting was
used to change the aliasing velocity until a clear
delineation of isovelocity slope was observed.
AVP was then automatically calculated by divid-
ing the distance between points corresponding to
the beginning and end of the propagation slope by
the duration between corresponding time points.
Thus, AVP corresponded to the velocity at which
the flow was propagating down the artery. The
mean of at least three measurements was
recorded as AVP value. AVP > 60 cm/s was con-
sidered normal [21].
BART was performed using a linear 7 MHz
transducer (Vivid 7, GE Healthcare), and both
groups were directed to abstain from caffeine 12
hours prior to the study. A longitudinal image
was used to measure brachial artery diameter
(1st baseline image), and a blood-pressure cuff
was inflated on the upper arm (2–5 cm above the
cubital fossa) to 50 mmHg above systolic pressure
Table 1. Baseline criteria of patients with metabolic syndrome.
Number Total (%)
Large WC 84 100
HTN 45 53
Newly diagnosed HTN 17 20
Medications 15
FBS > 100 56 66
Diabetes mellitus 22 26
Newly diagnosed diabetes 10
Medications 5
TC > 200 48 57
TG > 150 37 44
Low HDL 26 30
Newly diagnosed dyslipidemia 12
Medications 30
Visible epicardial fat 84 100
Fatty liver 43 51
Diastolic dysfunction 59 70
High filling pressure 10 13
IVS > 12 mm 43 51
AVP < 0.6 84 100
FMD < 10% 83 98
High AST 22 26
High ALT 23 27
High CRP 13 15
ALT = alanine transaminase; AST = aspartate transaminase;
AVP = aortic velocity propagation; CRP = c-reactive protein;
FBS = fasting blood sugar; FMD = flow-mediated dilatation;
HDL = high-density lipoprotein; HTN = hypertension; IVS = interven-
tricular septum; TG = triglycerides; TC = total cholesterol; WC = waist
circumference.
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ARTERIAL STIFFNESS IN METABOLIC SYNDROMEfor 5 minutes and then deflated after 1 minute. A
second longitudinal scan was obtained (from the
same position) to calculate the brachial artery
diameter (post-occlusion value). Flow-mediated
dilation (FMD) was calculated as:
maximum diameter during reactive hyperemia
 diameter at baselineÞ  100=ðdiameter at baselineÞ: ð1Þ
All measurements of the brachial artery lumen
diameter were assessed at end diastole.Table 2. Comparison of baseline characteristics and laboratory fin
(Group 2).
Group 1 (n = 84)
Female (%) 47 (55)
Age (y) 44 ± 9
WC (cm) 116 ± 10
TC (mg/dL) 204 ± 37
TG (mg/dL) 213 ± 98
HDL (mg/dL) 37 ± 6
ALT (U/L) 57 ± 18
AST (U/L) 50 ± 18
FBS (mg/dL) 121 ± 8
Serum creatinin (mg/dL) 0.96
Systolic BP (mmHg) 145 ± 16
diastolic BP (mmHg) 95 ± 8
ALT = alanine transaminase; AST = aspartate transaminase; BP = blood p
NS = non-significant; S = significant; TG = triglycerides; TC = total cholesteroStatistical analysis was performed using Micro-
soft Excel (Microsoft Office 2011; Microsoft, Inc.,
Redmond, WA, USA). All data were expressed
as mean ± standard deviation. The difference
between two means was statistically analyzed
using the Student t test. Pearson’s correlation
coefficient (r) was calculated to test the association
between two variables. Significance determined
as p < 0.05.3. Results
Eighty-four patients were studied in Group 1,
with 16/100 patients having difficult suprasternal
echo windows and, therefore, excluded from the
study. All normal individuals in Group 2 had fea-
sable echo windows.
All of the patients in Group 1 had large waist cir-
cumference (WC), visible epicardial fat, and
AVP < 60 cm/s. Forty-five patients had high blood
pressure, with 17 being newly diagnosed and only
15 receiving medication (Table 1).
While 22/84 patients had high AST levels and
23/84 patients had high ALT levels, none had
abnormal viral hepatitis markers and all of them
had variable degrees of fatty liver as detected by
abdominal ultrasonography.
Group 1 WC ranged from 104 cm to 119 cm, with
a mean of 116 ± 10 cm. Their TC ranged from
189 mg% to 296 mg%, with a mean of 204 ± 37 mg
%. Their TG ranged from 130 mg% to 280 mg%,
with a mean of 213 ± 98 mg%. Their HDL levels
ranged from 31 mg% to 52 mg%, with a mean of
37 ± 6 mg%, and their systolic blood pressure
SBP ranged from 120 mmHg to 160 mmHG, with
a mean of 145 ± 16 mmHG. Their DBP ranged
from 70 mmHg to 100 mmHg, with a mean of
95 ± 8 mmHG, and their FBS ranged from 80 mg%dings in metabolic syndrome patients (Group 1) and controls
Group 2 (n = 14) p Significance
7 (50) 0.7 NS
39 ± 7 0.2 NS
101 ± 1 <0.05 S
175 ± 21 <0.05 S
144 ± 22 <0.05 S
41 ± 6 <0.05 S
41 ± 21 <0.05 S
38 ± 15 <0.05 S
102 ± 11 <0.05 S
0.91 0.11 NS
120 ± 10 <0.05 S
73 ± 4 <0.05 S
ressure; FBS = fasting blood sugar; HDL = high-density lipoprotein;
l; WC = waist circumference.
Table 3. Echocardiography and brachial artery reactivity
findings.
Variables Group 1 Group 2 p
LVEF (%) 62 ± 7 64 ± 5 0.75
IVS (mm) 11 ± 2 9 ± 1 <0.05
E/e0 (%) 9 ± 1 7.5 ± 1 <0.05
AVP (cm/s) 36 ± 5 57 ± 5 <0.05
FMD (%) 6 ± 1 17 ± 3 <0.05
AVP = aortic velocity propagation; FMD = flow-mediated dilatation;
IVS = interventricular septum; LVEF = left ventricular ejection fraction.
Table 4. Correlation of AVP and different parameters.
Parameter r p Significance
FMD 0.89 <0.001 S
WC 0.48 <0.001 S
TC 0.23 0.09 NS
TG 0.11 0.87 NS
HDL 0.04 0.867 NS
SBP 0.4 <0.001 S
DBP 0.59 <0.001 S
FBS 0.14 0.134 NS
UA 0.3 0.98 NS
EPF 0.53 0.056 NS
IVS 0.39357 0.745 NS
E/e 0.37 <0.001 S
AST 0.1 0.96 NS
ALT 0.2 0.43 NS
CRP 0.44 <0.001 S
ALT = alanine transaminase; AST = aspartate transaminase;
AVP = aortic velocity propagation; CRP = c-reactive protein;
DBP = diastolic blood pressure; E/e0 = filling pressure; FBS = fasting
blood sugar; FMD = flow-mediated dilatation; EPF = epicardial fat;
HDL = high-density lipoprotein; HTN = hypertension; IVS = interven-
tricular septum; SBP = systolic blood pressure; TG = triglycerides;
TC = total cholesterol; UA = uric acid; WC = waist circumference.
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UA ranged from 4 mg% to 8.8 mg%, with a
mean of 7±1 mg%. Their AST ranged from
26 U to 76 U, with a mean of 50 ± 18 U, and
their ALT ranged from 20 U to 121 U, with a
mean of 57 ± 18 U.
There was no significant differences between
the two groups concerning age, gender, or serum
creatinine level, while there was significant dif-
ferences concerning the reminaing criteria
(Table 2). Thirteen patients in Group 1 had high
CRP, while none of the patients in Group 2 had
high CRP.
Echo criteria for Group 1 included IVS ranging
from 8 mm to 13 mm, with a mean of 11 ± 2 mm,
an E/e0 from 6% to 10%, with a mean of 9 ± 1%,
an AVP ranging from 29 cm/s to 48 cm/s, with a
mean of 36 ± 5 cm/s, and an FMD ranging from
5% to 9%, with a mean of 6 ± 1%.
The two groups did not differ significantly con-
cerning EF, while Group 1 had higher IVS and
E/e0 and lower AVP and FMD (Table 3). The
AVP correlated positevely with FMD (r = 0.89;
Fig. 1), AVP correlated negatively with DBP
(r = 0.59), WC (r = 0.48), SBP (r = 0.42), CRP
(r = 0.44), and E/e0 (r = 0.39). The rest of the
parameters did not show significant correlations
(Table 4).Figure 1. Significant correlation between AVP and FMD. AVP = aortic ve4. Discussion
We studied 84 patients with MS. All of them dis-
played aortic stiffness, as they had significantly
reduced AVP (as a parameter of aortic stiffness)
as compared to the Group 2. Additionally, they
showed reduced FMD, indicating endothelial dys-
function, and 26% of them had high liver enzymes
and 15% had high CRP. There was a significant
correlation between AVP, FMD, and high CRP,
indicationg a possible link between aortic stiff-
ness, endothelial dysfunction, and inflammation
(Figs. 2 and 3).
The existence of a strong association between
the presence of MS, arterial stiffness, and inflam-
mation has been shown in many cross-sectional
studies [6,22]. MS is a cluster of commonlocity propagation; FMD = flow-mediated dilatation.
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Figure 2. Color M-Mode at descending aorta from suprasternal area in a patient with metabolic syndrome. AVP = 24 cm/s. AVP = aortic velocity
propagation.
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ARTERIAL STIFFNESS IN METABOLIC SYNDROMEpathologies, including abdominal obesity linked
to an excess of visceral fat, insulin resistance, dys-
lipidemia, and hypertension [1]. At the molecular
level, MS is accompanied by abnormal regulation
adipokine expression (cytokines and chemokines),
making MS an inflammatory condition [22,23],
which may explain the high CRP in some of our
patients.
As several cytokines are also produced by adi-
pose tissue [28], it was postulated that an
‘‘adipo-vascular’’ axis [24,25] may contribute to
the increased risk of cardiovascular events in
patients with MS. As it expresses itself in lower
plasma levels of adiponectin and higher plasma
levels of IL-6, this could be linked to the develop-
ment of arterial stiffness, microvascular dysfunc-
tion, and inflammation [26,27]. Inflammation
increases insulin resistance, which, in turn, leads
to obesity while propagating diabetes, high blood
pressure, prothrombotic states, and dyslipidemia
[24].Early in the course of diabetes and MS, intracel-
lular hyperglycemia due to insulin resistance
causes changes in blood flow and increased vascu-
lar permeability. This reflects decreased activity of
nitric oxide, and increased activity of angiotensin
II and endothelin-1. Angiotensin II produces acute
vasoconstriction, leading to an increase in blood
pressure, and endothelin-1 is an important regu-
lator of vascular tone and has been implicated in
the pathogenesis of endothelial dysfunction and
atherosclerosis [7,28,29].
Additionally, abnormalities of the extracellular
matrix contribute to an irreversible increase in
vascular permeability. Hyperglycemia itself leads
not only to decreased endothelial production of
nitric oxide, which represents an anti-
atherogenic molecule, but also increased produc-
tion of a potent inhibitor of fibrinolysis, namely
plasminogen activator inhibitor 1 [30]. The risk
factors for MS, either together or individually,
are also associated with arterial stiffness and
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Figure 3. Color M-Mode at descending aorta from suprasternal area in a normal subject. AVP = 52 cm/s. AVP = aortic velocity propagation.
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ease [31–35].
Systemic endothelial function reflects the
propensity of arteries to develop atherosclerosis
in response to exposure to cardiovascular risk fac-
tors. Atherosclerosis leads to increased arterial
resistance through thickening and stiffening of
the arterial wall. Because the increased aortic
resistance acts in a manner to decrease the flow-
propagation speed within the arterial lumen, a
similar decrease in aortic flow propagation with
increased downstream resistance is logical [36],
therefore, AVP was studied in many studies as a
new parameter of aortic stiffness, endothelial dys-
function, and atherosclerosis. Gunes et al [18]
evaluated aortic strain, aortic distensibility, aorto-
femoral pulse-wave propagation velocity, andAVP in 127 patients undergoing coronary angiog-
raphy and found that among clinical and echocar-
diographic variables, AVP was the most
significant predictor of coronary artery disease,
and that an AVP 6 41 cm/s predicted coronary
artery disease with 82.4% sensitivity and 97.2%
specificity (positive predictive value: 98.7%; nega-
tive predictive value: 68.2%). Gunes et al [37] later
measured AVP to predict subclinical atherosclero-
sis. Sismek et al [38] found that AVP measured by
transthoracic echocardiography was decreased in
patients with coronary slow flow and significantly
correlated with FMD. The correlation between
FMD and AVP was r = 0.524 (p < 0.001), which
agreed with our results, as we also found correla-
tions between the two parameters (r = 0.89,
p < 0.001).
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ARTERIAL STIFFNESS IN METABOLIC SYNDROMEYildirim et al [39] compared AVP with the Fram-
ingham coronary risk score, carotid intima media
thickness, and high-sensitive CRP and found out
that AVP was significantly lower (p < 0.001) and
carotid intima media thickness and high-
sensitive CRP were significantly higher in high-
risk hypertensive patients. These results aggree
with our findings, as we found that AVP was sig-
nificantly lower and CRP significantly higher in
our studied patients.
Gunes et al [40] also found significant associa-
tions between AVP, carotid intima media thick-
ness, and FMD in patients having significant
coronary atherosclerosis. AVP was also useful in
improving the diagnostic accuracy of the exercise
electrocardiography test [19]. Twenty-six percent
of our patients had high liver enzymes that may
have been due to liver inflammation secondary
to non-alcoholic fatty liver disease (NAFLD). The
progression of NAFLD in MS may be explained
by steatosis caused by the initial metabolic distur-
bance and oxidative stress due to reactive oxygen
species formation and cytokine production [41,42].
Previous studies showed a relationship between
NAFLD and atherosclerosis [43,44], however, we
did not find any correlation between AVP, fatty
liver, and high liver enzymes, which agrees with
findings by Poanta et al [45].
AVP is a new non-invasive method that is sim-
ple, easily applicable, inexpensive, and does not
require complex insturments. It is also very reli-
able and correlates significantly with almost all
indices of arterial stiffness and atherosclerosis,
meaning that it can be used to improve noninva-
sive assessment of global cardiovascular risk in
many situations to improve selection of high-risk
individuals for additional investigation.5. Conclusion
Patients with MS suffer from endothelial dys-
function and arterial stiffness. Transthoracic
echocardiographic-detected AVP is a simple,
easily applicable method for detection of arterial
stiffness that can be used in a wide range of situ-
ations for better cardiovascular risk assessment.
Our study had limitations: (1) FBS was not mea-
sured as glycosylated hemoglobin, as it is not
one of the criteria necessary for the diagnosis of
MS; (2) we had fewer normal patients in Group
2, because of the difficulty in finding individuals
seeking medical help during the interval of the
study; (3) CRP was measured to detect inflamma-
tion and not high-sensitive CRP, as it was not
available in our hospital at the time of the study;and (4) an inadequate suprasternal window was
considered a limitation of AVP measurement.Conflict of interest
The authors declare no conflicts of interest.References
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